Showing results (1-10 of 33) with videos related to
Sort By:
Pageof 4
Cell Cycle (Georgetown, Tex.)|September 10, 2003
A G2/M cell cycle block in transformed cells by contact with normal neighborsDavid Allard, Michael Stoker, Ermanno GherardiMethods in Molecular Biology (Clifton, N.J.)|September 2, 2016
Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical StudiesBertrand Allard, David Allard, John StaggJournal for Immunotherapy of Cancer|February 27, 2020
On the mechanism of anti-CD39 immune checkpoint therapyDavid Allard, Bertrand Allard, John StaggImmunology and Cell Biology|February 9, 2017
Targeting A2 adenosine receptors in cancerDavid Allard, Martin Turcotte, John StaggSeminars in Immunology|October 13, 2019
Targeting the adenosine pathway for cancer immunotherapyAkil Hammami, David Allard, Bertrand Allard, et al.Nature Reviews. Clinical Oncology|June 10, 2020
The adenosine pathway in immuno-oncologyBertrand Allard, David Allard, Laurence Buisseret, et al.Nature Reviews. Clinical Oncology|July 19, 2020
Publisher Correction: The adenosine pathway in immuno-oncologyBertrand Allard, David Allard, Laurence Buisseret, et al.Methods in Molecular Biology (Clifton, N.J.)|December 31, 2022
Assessing the Efficacy of Immune Checkpoint Inhibitors in Preclinical Tumor ModelsCelia Jacoberger-Foissac, Bertrand Allard, David Allard, et al.Immunology Letters|May 15, 2018
Targeting the CD73-adenosine axis in immuno-oncologyDavid Allard, Pavel Chrobak, Bertrand Allard, et al.Plos One|January 30, 2018
CD73-A2a adenosine receptor axis promotes innate B cell antibody responses to pneumococcal polysaccharide vaccinationDavid Allard, Roxanne Charlebois, Loise Gilbert, et al.Pageof 4